NEW YORK and HAIKOU CITY, China, July 3 /Xinhua-PRNewswire/ -- China Pharma Holdings, Inc. (“China Pharma”) (OTC Bulletin Board: CPHI) which develops, manufactures, and markets generic and branded bio-pharmaceutical products in China, today announced that the management will present at the Collins Stewart Fourth Annual Growth Conference on Tuesday, July 8th at 2:00 p.m. EDT. The conference is being held at the Mandarin Oriental Hotel in New York City, NY.
Mr. Xinhua Wu, China Pharma's CFO, and two senior managers Mr. Sam Hsing and Ms. Mary Wyatt will be representing China Pharma at the conference and will be available for one-on-one meetings with analysts and investors throughout the day. Mr. Hsing and Ms. Wyatt joined the Company recently. Mr. Hsing holds a Master degree in finance from University of Plymouth. Ms. Wyatt graduated from Manchester University with a BS in Molecular Biology and has studied and worked in China since 1999. They are both English-speaking members of senior management and will assist the Company in public financial and investor communications.
Management will discuss the Company's current product portfolio, development pipeline, research and development platform, recent financial highlights and its long-term growth strategy.
Participation is by invitation and registration is mandatory. For more information on the conference contact your Collins Stewart representative or visit http://www.collins-stewart.com .
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. develops, manufactures, and markets generic and brand bio-pharmaceutical products in China that treat a wide range of conditions, including infections, hepatitis, cardiovascular and CNS diseases, and other prevailing diseases. Helpson Bio-pharmaceutical Co., Ltd (Helpson), a specialty pharmaceutical company headquartered in Haikou City, Hainan province in China, is a wholly owned subsidiary of China Pharma Holdings. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com .
Safe Harbor Statement:
Certain statements in this press release and oral statements made by China Pharma on its conference call in relation to this release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand, increased competition, failure to obtain or maintain intellectual property protection, downturns in the Chinese economy, uncompetitive levels of research and development, failure to obtain regulatory approvals, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations.
